Abbisko Cayman Limited (HKG:2256)
Hong Kong
· Delayed Price · Currency is HKD 9.84
+0.08 (0.82%)
Jul 14, 2025, 4:08 PM HKT
Abbisko Cayman Revenue
In the year 2024, Abbisko Cayman had annual revenue of 503.99M CNY with 2,544.24% growth. Abbisko Cayman had revenue of 6.72M in the half year ending December 31, 2024.
Revenue
503.99M CNY
Revenue Growth
+2,544.24%
P/S Ratio
11.31
Revenue / Employee
1.79M CNY
Employees
281
Market Cap
6.06B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| Innovent Biologics | 10.03B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Sino Biopharmaceutical | 30.72B |
| Akeso | 2.26B |
| CSPC Pharmaceutical Group | 28.99B |